Release Date: August 29, 2025
Expiration Date: August 29, 2026
Activity Overview
In this program, a panel of retina specialists share their insights into the use of newer anti-VEGF agents, which offer the opportunity for extended treatment intervals for the treatment of retinal vein occlusion (RVO), neovascular age-related macular degeneration, and diabetic macular edema. Featured in the program are discussions of recently presented data for these therapies, illustrative cases, and suggestions regarding ways to improve the comanagement of these diseases between retina specialists, optometrists, and general ophthalmologists.
Target Audience
These educational activities are directed toward optometrists, ophthalmologists, and other health care professionals involved in the management of patients with neovascular retinal diseases.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Recognize the clinical features of RVO using advanced imaging techniques.
- Define appropriate referral efficiency and comanagement between optometrists and retina specialists in the management of nAMD.
- Evaluate the latest clinical trial data on next-generation anti-VEGF therapies and their implications for extended dosing intervals in nAMD management.
- Classify effective patient communication strategies to address concerns about intravitreal therapy and optimize treatment adherence for patients with DME.